NASDAQ:PLSE - Nasdaq - US74587B1017 - Common Stock - Currency: USD
19.47
-0.53 (-2.65%)
The current stock price of PLSE is 19.47 USD. In the past month the price increased by 9.26%. In the past year, price increased by 113.49%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 56 full-time employees. The company went IPO on 2016-05-18. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The firm is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The firm has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 56
Company Website: https://www.pulsebiosciences.com/
Investor Relations: https://investors.pulsebiosciences.com/
Phone: 15109064600
The current stock price of PLSE is 19.47 USD. The price decreased by -2.65% in the last trading session.
The exchange symbol of PULSE BIOSCIENCES INC is PLSE and it is listed on the Nasdaq exchange.
PLSE stock is listed on the Nasdaq exchange.
PULSE BIOSCIENCES INC (PLSE) has a market capitalization of 1.20B USD. This makes PLSE a Small Cap stock.
PULSE BIOSCIENCES INC (PLSE) currently has 56 employees.
PULSE BIOSCIENCES INC (PLSE) has a support level at 18.77 and a resistance level at 21.78. Check the full technical report for a detailed analysis of PLSE support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PLSE does not pay a dividend.
PULSE BIOSCIENCES INC (PLSE) will report earnings on 2025-03-26, after the market close.
PULSE BIOSCIENCES INC (PLSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).
The outstanding short interest for PULSE BIOSCIENCES INC (PLSE) is 18.02% of its float. Check the ownership tab for more information on the PLSE short interest.
ChartMill assigns a technical rating of 7 / 10 to PLSE. When comparing the yearly performance of all stocks, PLSE is one of the better performing stocks in the market, outperforming 95.49% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to PLSE. PLSE has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 55.68% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -49.58% | ||
ROE | -58.3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to PLSE. The Buy consensus is the average rating of analysts ratings from 6 analysts.